Drug profile · INN
lithium carbonate
LITHICARB
lithium carbonate (LITHICARB) is a glycogen synthase kinase-3 inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — lithium carbonate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 5
- Data quality
- 0.84
Quick answer
lithium carbonate (LITHICARB) is a glycogen synthase kinase-3 inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Glycogen synthase kinase-3 inhibitor
Primary target: Glycogen synthase kinase-3
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is lithium carbonate?
lithium carbonate (LITHICARB) is a glycogen synthase kinase-3 inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for lithium carbonate?
LITHICARB is a marketed brand name for lithium carbonate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of lithium carbonate?
lithium carbonate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.